{
  "protocolSection": {
  "identificationModule": {
  "nctId": "NCT01234567",
  "orgStudyIdInfo": {
  "id": "ACU-D1"
  },
  "organization": {
  "fullName": "Accuitis, Inc.",
  "class": "INDUSTRY"
  },
  "briefTitle": "Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea",
  "officialTitle": "A RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, PROOF-OF CONCEPT STUDY OF THE SAFETY AND EFFICACY OF ACU-D1 OINTMENT IN SUBJECTS WITH ACNE ROSACEA"
  },
  "statusModule": {
  "statusVerifiedDate": "2021-08",
  "overallStatus": "COMPLETED",
  "expandedAccessInfo": {
  "hasExpandedAccess": false
  },
  "startDateStruct": {
  "date": "2017-11-28",
  "type": "ACTUAL"
  },
  "primaryCompletionDateStruct": {
  "date": "2018-06-05",
  "type": "ACTUAL"
  },
  "completionDateStruct": {
  "date": "2018-06-18",
  "type": "ACTUAL"
  },
  "studyFirstSubmitDate": "2017-02-22",
  "studyFirstSubmitQcDate": "2017-02-24",
  "studyFirstPostDateStruct": {
  "date": "2017-02-27",
  "type": "ACTUAL"
  },
  "resultsFirstSubmitDate": "2021-08-17",
  "resultsFirstSubmitQcDate": "2021-08-17",
  "resultsFirstPostDateStruct": {
  "date": "2021-08-23",
  "type": "ACTUAL"
  },
  "lastUpdateSubmitDate": "2021-08-17",
  "lastUpdatePostDateStruct": {
  "date": "2021-08-23",
  "type": "ACTUAL"
  }
  },
  "sponsorCollaboratorsModule": {
  "responsibleParty": {
  "type": "SPONSOR"
  },
  "leadSponsor": {
  "name": "Accuitis, Inc.",
  "class": "INDUSTRY"
  }
  },
  "oversightModule": {
  "oversightHasDmc": false,
  "isFdaRegulatedDrug": true,
  "isFdaRegulatedDevice": false,
  "isUsExport": false,
  "fdaaa801Violation": true
  },
  "descriptionModule": {
  "briefSummary": "The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of the participants received ACCU-D1 while one-third of the participants received vehicle control."
  },
  "conditionsModule": {
  "conditions": [
  "Acne Rosacea"
  ]
  },
  "designModule": {
  "studyType": "INTERVENTIONAL",
  "phases": [
  "PHASE2"
  ],
  "designInfo": {
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "primaryPurpose": "TREATMENT",
  "maskingInfo": {
  "masking": "DOUBLE",
  "whoMasked": [
  "PARTICIPANT",
  "INVESTIGATOR"
  ]
  }
  },
  "enrollmentInfo": {
  "count": 40,
  "type": "ACTUAL"
  }
  },
  "armsInterventionsModule": {
  "armGroups": [
  {
  "label": "ACU-D1 Ointment",
  "type": "EXPERIMENTAL",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks.",
  "interventionNames": [
  "Drug: ACCU-D1"
  ]
  },
  {
  "label": "ACU-D1 Ointment Vehicle",
  "type": "PLACEBO_COMPARATOR",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.",
  "interventionNames": [
  "Drug: Vehicle"
  ]
  }
  ],
  "interventions": [
  {
  "type": "DRUG",
  "name": "ACCU-D1",
  "description": "ACCU-D1",
  "armGroupLabels": [
  "ACU-D1 Ointment"
  ]
  },
  {
  "type": "DRUG",
  "name": "Vehicle",
  "description": "Placebo Comparator",
  "armGroupLabels": [
  "ACU-D1 Ointment Vehicle"
  ]
  }
  ]
  },
  "outcomesModule": {
  },
  "eligibilityModule": {
  "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant is male or non-pregnant and non-lactating female at least 18 years of age\n* Participant has a clinical diagnosis of stable papulopustular rosacea (type-2)\n* Participant has a total of ≥10 and ≤40 inflammatory lesions (papules, pustules, and nodules) on the face\n* Participant has ≤2 nodules on the face\n* Participant has an investigator's global assessment (IGA) score of ≥3\n* If the participant is a woman of childbearing potential, she has a negative urine pregnancy test and agrees to use an approved effective method of birth control for the duration of the study\n* Participant is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair evaluation of rosacea or which exposes the participant to an unacceptable risk by study participation\n* Participant is willing and able to follow all study instructions and to attend all study visits\n* Participant is able to comprehend and willing to sign an informed consent form\n\nExclusion Criteria:\n\n* Participant is pregnant, nursing, or planning to become pregnant during the duration of the study\n* Participant has used systemic glucocorticosteroids within 42 days prior to Visit 1 (inhaled and ocular glucocorticosteroids are permitted)\n* Participant has used systemic antibiotics within 28 days prior to Visit 1\n* Participant has used any topical glucocorticosteroids on the face within 28 days prior to Visit 1\n* Participant has used any prescription or over-the-counter product for the treatment of acne or rosacea within 14 days prior to Visit 1\n* Participant is currently using any therapy that, in the investigator's opinion, is a photosensitizer (for example, phenothiazines, amiodarone, quinine, thiazides, sulphonamides, quinolones, etc.)\n* Participant currently has any skin disease (for example, psoriasis, atopic dermatitis, eczema), or condition (for example, actinic keratosis, photo-damage, sunburn, excessive hair, open wounds) that, in the investigator's opinion, might impair evaluation of rosacea or which exposes the subject to an unacceptable risk by study participation\n* Participant currently has, on the face, or has had on the face, any of the following within the specified period prior to Visit 1 that, in the investigator's opinion, might impair evaluation of rosacea or which exposes the subject to an unacceptable risk by study participation:\n\n  * A cutaneous malignancy; 180 days\n  * Experienced a sunburn; 14 days\n* Participant has facial hair, that in the investigator's opinion, might impair evaluation of rosacea or proper study medication application\n* Participant has a history of sensitivity to any of the ingredients in the study medications\n* Participant has participated in an investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to Visit 1",
  "healthyVolunteers": false,
  "sex": "ALL",
  "minimumAge": "18 Years",
  "stdAges": [
  "ADULT",
  "OLDER_ADULT"
  ]
  },
  "contactsLocationsModule": {
  "locations": [
  {
  "facility": "DS Research",
  "city": "Louisville",
  "state": "Kentucky",
  "zip": "40421",
  "country": "United States",
  "geoPoint": {
  "lat": 38.25424,
  "lon": -85.75941
  }
  },
  {
  "facility": "DermResearch",
  "city": "Austin",
  "state": "Texas",
  "zip": "78759",
  "country": "United States",
  "geoPoint": {
  "lat": 30.26715,
  "lon": -97.74306
  }
  }
  ]
  },
  "referencesModule": {
  "references": [
  {
  "pmid": "34076401",
  "type": "DERIVED",
  "citation": "Jackson JM, Coulon R, Arbiser JL. Evaluation of a First-in-Class Proteasome Inhibitor in Patients With Moderate to Severe Rosacea. J Drugs Dermatol. 2021 Jun 1;20(6):660-664. doi: 10.36849/JDD.2021.5925."
  }
  ]
  },
  "ipdSharingStatementModule": {
  "ipdSharing": "NO"
  }
  },
  "resultsSection": {
  "participantFlowModule": {
  "preAssignmentDetails": "Eligible participants will be assigned in a random manner to 1 of the 2 study medications in a 2:1 ratio (ACU-D1 ointment: ACU-D1 ointment vehicle).",
  "recruitmentDetails": "The study was conducted at two sites in the United States.",
  "groups": [
  {
  "id": "FG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks."
  },
  {
  "id": "FG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks."
  }
  ],
  "periods": [
  {
  "title": "Overall Study",
  "milestones": [
  {
  "type": "STARTED",
  "achievements": [
  {
  "groupId": "FG000",
  "numSubjects": "27"
  },
  {
  "groupId": "FG001",
  "numSubjects": "13"
  }
  ]
  },
  {
  "type": "COMPLETED",
  "achievements": [
  {
  "groupId": "FG000",
  "numSubjects": "26"
  },
  {
  "groupId": "FG001",
  "numSubjects": "12"
  }
  ]
  },
  {
  "type": "NOT COMPLETED",
  "achievements": [
  {
  "groupId": "FG000",
  "numSubjects": "1"
  },
  {
  "groupId": "FG001",
  "numSubjects": "1"
  }
  ]
  }
  ],
  "dropWithdraws": [
  {
  "type": "Lost to Follow-up",
  "reasons": [
  {
  "groupId": "FG000",
  "numSubjects": "1"
  },
  {
  "groupId": "FG001",
  "numSubjects": "0"
  }
  ]
  },
  {
  "type": "Withdrawal by Subject",
  "reasons": [
  {
  "groupId": "FG000",
  "numSubjects": "0"
  },
  {
  "groupId": "FG001",
  "numSubjects": "1"
  }
  ]
  }
  ]
  }
  ]
  },
  "baselineCharacteristicsModule": {
  "populationDescription": "The modified intention-to-treat (MITT) population included all randomized participants who were dispensed study medication and provided any post-baseline efficacy data.",
  "groups": [
  {
  "id": "BG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks."
  },
  {
  "id": "BG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks."
  },
  {
  "id": "BG002",
  "title": "Total",
  "description": "Total of all reporting groups"
  }
  ],
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "BG000",
  "value": "27"
  },
  {
  "groupId": "BG001",
  "value": "13"
  },
  {
  "groupId": "BG002",
  "value": "40"
  }
  ]
  }
  ],
  "measures": [
  {
  "title": "Age, Continuous",
  "paramType": "MEAN",
  "dispersionType": "STANDARD_DEVIATION",
  "unitOfMeasure": "years",
  "classes": [
  {
  "categories": [
  {
  "measurements": [
  {
  "groupId": "BG000",
  "value": "49.59",
  "spread": "11.537"
  },
  {
  "groupId": "BG001",
  "value": "51.08",
  "spread": "12.473"
  },
  {
  "groupId": "BG002",
  "value": "50.08",
  "spread": "11.708"
  }
  ]
  }
  ]
  }
  ]
  },
  {
  "title": "Sex: Female, Male",
  "paramType": "COUNT_OF_PARTICIPANTS",
  "unitOfMeasure": "Participants",
  "classes": [
  {
  "categories": [
  {
  "title": "Female",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "23"
  },
  {
  "groupId": "BG001",
  "value": "11"
  },
  {
  "groupId": "BG002",
  "value": "34"
  }
  ]
  },
  {
  "title": "Male",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "4"
  },
  {
  "groupId": "BG001",
  "value": "2"
  },
  {
  "groupId": "BG002",
  "value": "6"
  }
  ]
  }
  ]
  }
  ]
  },
  {
  "title": "Ethnicity (NIH/OMB)",
  "paramType": "COUNT_OF_PARTICIPANTS",
  "unitOfMeasure": "Participants",
  "classes": [
  {
  "categories": [
  {
  "title": "Hispanic or Latino",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "5"
  },
  {
  "groupId": "BG001",
  "value": "0"
  },
  {
  "groupId": "BG002",
  "value": "5"
  }
  ]
  },
  {
  "title": "Not Hispanic or Latino",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "22"
  },
  {
  "groupId": "BG001",
  "value": "13"
  },
  {
  "groupId": "BG002",
  "value": "35"
  }
  ]
  },
  {
  "title": "Unknown or Not Reported",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "0"
  },
  {
  "groupId": "BG001",
  "value": "0"
  },
  {
  "groupId": "BG002",
  "value": "0"
  }
  ]
  }
  ]
  }
  ]
  },
  {
  "title": "Race (NIH/OMB)",
  "paramType": "COUNT_OF_PARTICIPANTS",
  "unitOfMeasure": "Participants",
  "classes": [
  {
  "categories": [
  {
  "title": "American Indian or Alaska Native",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "0"
  },
  {
  "groupId": "BG001",
  "value": "0"
  },
  {
  "groupId": "BG002",
  "value": "0"
  }
  ]
  },
  {
  "title": "Asian",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "0"
  },
  {
  "groupId": "BG001",
  "value": "0"
  },
  {
  "groupId": "BG002",
  "value": "0"
  }
  ]
  },
  {
  "title": "Native Hawaiian or Other Pacific Islander",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "0"
  },
  {
  "groupId": "BG001",
  "value": "0"
  },
  {
  "groupId": "BG002",
  "value": "0"
  }
  ]
  },
  {
  "title": "Black or African American",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "0"
  },
  {
  "groupId": "BG001",
  "value": "0"
  },
  {
  "groupId": "BG002",
  "value": "0"
  }
  ]
  },
  {
  "title": "White",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "27"
  },
  {
  "groupId": "BG001",
  "value": "13"
  },
  {
  "groupId": "BG002",
  "value": "40"
  }
  ]
  },
  {
  "title": "More than one race",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "0"
  },
  {
  "groupId": "BG001",
  "value": "0"
  },
  {
  "groupId": "BG002",
  "value": "0"
  }
  ]
  },
  {
  "title": "Unknown or Not Reported",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "0"
  },
  {
  "groupId": "BG001",
  "value": "0"
  },
  {
  "groupId": "BG002",
  "value": "0"
  }
  ]
  }
  ]
  }
  ]
  },
  {
  "title": "Total lesion count",
  "description": "Total lesion count was the sum of counts of the following lesion types (face only): Papule - raised inflammatory lesions, \\< 0.5 cm in diameter with no visible purulent material; Pustule - raised inflammatory lesions, \\< 0.5 cm in diameter with visible purulent material; Nodule - any circumscribed, inflammatory mass ≥ 0.5 cm in diameter.",
  "paramType": "MEAN",
  "dispersionType": "STANDARD_DEVIATION",
  "unitOfMeasure": "number of lesions",
  "classes": [
  {
  "categories": [
  {
  "measurements": [
  {
  "groupId": "BG000",
  "value": "18.00",
  "spread": "9.413"
  },
  {
  "groupId": "BG001",
  "value": "20.46",
  "spread": "9.777"
  },
  {
  "groupId": "BG002",
  "value": "18.80",
  "spread": "9.479"
  }
  ]
  }
  ]
  }
  ]
  },
  {
  "title": "Erythema score based on local tolerability as assessed by the investigator",
  "description": "Erythema score at baseline (pre-application) was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.\n\nScore 0 (clear): no erythema present; Score 1 (mild): slight erythema; Score 2 (moderate): definite erythema; Score 3 (severe): marked, fiery erythema. The assessment was based on the safety population which included all randomized participants who received at least 1 dose of study medication.",
  "paramType": "COUNT_OF_PARTICIPANTS",
  "unitOfMeasure": "Participants",
  "classes": [
  {
  "categories": [
  {
  "title": "Score 0 (clear)",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "1"
  },
  {
  "groupId": "BG001",
  "value": "1"
  },
  {
  "groupId": "BG002",
  "value": "2"
  }
  ]
  },
  {
  "title": "Score 1 (mild)",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "5"
  },
  {
  "groupId": "BG001",
  "value": "4"
  },
  {
  "groupId": "BG002",
  "value": "9"
  }
  ]
  },
  {
  "title": "Score 2 (moderate)",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "16"
  },
  {
  "groupId": "BG001",
  "value": "5"
  },
  {
  "groupId": "BG002",
  "value": "21"
  }
  ]
  },
  {
  "title": "Score 3 (severe)",
  "measurements": [
  {
  "groupId": "BG000",
  "value": "5"
  },
  {
  "groupId": "BG001",
  "value": "3"
  },
  {
  "groupId": "BG002",
  "value": "8"
  }
  ]
  }
  ]
  }
  ]
  }
  ]
  },
  "outcomeMeasuresModule": {
  "outcomeMeasures": [
  {
  "type": "PRIMARY",
  "title": "Change From Baseline in Total Lesion Count at Week 12",
  "description": "Total lesion count was the sum of counts of the following lesion types (face only): Papule - raised inflammatory lesions, \\<0.5 cm in diameter with no visible purulent material; Pustule - raised inflammatory lesions, \\<0.5 cm in diameter with visible purulent material; Nodule - any circumscribed, inflammatory mass ≥0.5 cm in diameter.",
  "populationDescription": "Number of participants included participants in the MITT population with available data at Week 12.",
  "reportingStatus": "POSTED",
  "paramType": "LEAST_SQUARES_MEAN",
  "dispersionType": "Standard Error",
  "unitOfMeasure": "number of lesions",
  "timeFrame": "Baseline, Week 12",
  "groups": [
  {
  "id": "OG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks."
  },
  {
  "id": "OG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks."
  }
  ],
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "26"
  },
  {
  "groupId": "OG001",
  "value": "11"
  }
  ]
  }
  ],
  "classes": [
  {
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-10.2",
  "spread": "1.08"
  },
  {
  "groupId": "OG001",
  "value": "-12.0",
  "spread": "1.62"
  }
  ]
  }
  ]
  }
  ],
  "analyses": [
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.366",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of Least Squares (LS) Mean",
  "paramValue": "1.8",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-2.162",
  "ciUpperLimit": "5.727",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "1.95"
  }
  ]
  },
  {
  "type": "SECONDARY",
  "title": "Percent Change From Baseline in Investigator's Global Assessment (IGA) Score at Weeks 2, 4, 8, and 12",
  "description": "The IGA score is an ordered categorical value ranging from 0 (clear) to 4 (severe). A lower score indicated improvement in the condition.\n\nScore 0 (clear): no papules or pustules, no nodules, none or barely perceptible erythema\n\nScore 1 (near clear): very few (≤3) papules and/or pustules, no nodules, very mild erythema\n\nScore 2 (mild): few papules and pustules present, no nodules, mild erythema\n\nScore 3 (moderate): several papules and pustules are the predominant features, ≤2 nodules may be present, moderate erythema\n\nScore 4 (severe): numerous papules and pustules, multiple nodules may be present, severe erythema",
  "populationDescription": "MITT population. Number of participants analyzed included participants with available data at specific timepoint.",
  "reportingStatus": "POSTED",
  "paramType": "MEAN",
  "dispersionType": "Standard Deviation",
  "unitOfMeasure": "percent change",
  "timeFrame": "Baseline; Weeks 2, 4, 8, and 12",
  "groups": [
  {
  "id": "OG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks."
  },
  {
  "id": "OG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks."
  }
  ],
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "classes": [
  {
  "title": "Week 2",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-23",
  "spread": "0.2561"
  },
  {
  "groupId": "OG001",
  "value": "-29",
  "spread": "0.1653"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 4",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-35",
  "spread": "0.2387"
  },
  {
  "groupId": "OG001",
  "value": "-26",
  "spread": "0.2771"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 8",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-31",
  "spread": "0.2538"
  },
  {
  "groupId": "OG001",
  "value": "-29",
  "spread": "0.2233"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 12",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "26"
  },
  {
  "groupId": "OG001",
  "value": "11"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-31",
  "spread": "0.2588"
  },
  {
  "groupId": "OG001",
  "value": "-26",
  "spread": "0.3583"
  }
  ]
  }
  ]
  }
  ],
  "analyses": [
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Percent change from baseline at Week 2",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.1099",
  "statisticalMethod": "Van Elteren test"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Percent change from baseline at Week 4",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.1653",
  "statisticalMethod": "Van Elteren test"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Percent change from baseline at Week 8",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.8437",
  "statisticalMethod": "Van Elteren test"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Percent change from baseline at Week 12",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.4644",
  "statisticalMethod": "Van Elteren test"
  }
  ]
  },
  {
  "type": "SECONDARY",
  "title": "Percentage of Participants Who Were Treatment Responders at Week 12",
  "description": "Treatment responders were defined as participants who have either (1) 2 ordinal or more reductions in the IGA score from baseline or (2) an IGA score of 0 or 1.\n\nThe IGA score is an ordered categorical value ranging from 0 (clear) to 4 (severe). A lower score indicated improvement in the condition.\n\nScore 0 (clear): no papules or pustules, no nodules, none or barely perceptible erythema\n\nScore 1 (near clear): very few (≤3) papules and/or pustules, no nodules, very mild erythema\n\nScore 2 (mild): few papules and pustules present, no nodules, mild erythema\n\nScore 3 (moderate): several papules and pustules are the predominant features, ≤2 nodules may be present, moderate erythema\n\nScore 4 (severe): numerous papules and pustules, multiple nodules may be present, severe erythema",
  "populationDescription": "MITT population. Number of participants analyzed included participants with available IGA score at Week 12.",
  "reportingStatus": "POSTED",
  "paramType": "NUMBER",
  "unitOfMeasure": "percentage of participants",
  "timeFrame": "Baseline, Week 12",
  "groups": [
  {
  "id": "OG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks."
  },
  {
  "id": "OG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks."
  }
  ],
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "26"
  },
  {
  "groupId": "OG001",
  "value": "11"
  }
  ]
  }
  ],
  "classes": [
  {
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "19.2"
  },
  {
  "groupId": "OG001",
  "value": "18.2"
  }
  ]
  }
  ]
  }
  ],
  "analyses": [
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "1.0",
  "statisticalMethod": "Fisher Exact"
  }
  ]
  },
  {
  "type": "SECONDARY",
  "title": "Change From Baseline in Papule Lesions at Weeks 2, 4, 8, and 12",
  "description": "Papule - raised inflammatory lesions, \\<0.5 cm in diameter with no visible purulent material",
  "populationDescription": "MITT population. Number of participants analyzed included participants with available data at specified visits.",
  "reportingStatus": "POSTED",
  "paramType": "LEAST_SQUARES_MEAN",
  "dispersionType": "Standard Error",
  "unitOfMeasure": "number of lesions",
  "timeFrame": "Baseline; Weeks 2, 4, 8, and 12",
  "groups": [
  {
  "id": "OG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks."
  },
  {
  "id": "OG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks."
  }
  ],
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "classes": [
  {
  "title": "Week 2",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-6.6",
  "spread": "1.09"
  },
  {
  "groupId": "OG001",
  "value": "-7.95",
  "spread": "1.57"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 4",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-9.7",
  "spread": "0.97"
  },
  {
  "groupId": "OG001",
  "value": "-8.22",
  "spread": "1.44"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 8",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-8.1",
  "spread": "1.16"
  },
  {
  "groupId": "OG001",
  "value": "-10.30",
  "spread": "1.71"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 12",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "26"
  },
  {
  "groupId": "OG001",
  "value": "11"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-9.2",
  "spread": "1.01"
  },
  {
  "groupId": "OG001",
  "value": "-10.98",
  "spread": "1.53"
  }
  ]
  }
  ]
  }
  ],
  "analyses": [
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 2",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.495",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "1.3",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-2.571",
  "ciUpperLimit": "5.211",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "1.91"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 4",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.399",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "-1.5",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-5.014",
  "ciUpperLimit": "2.045",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "1.74"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 8",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.290",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "2.2",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-1.965",
  "ciUpperLimit": "6.407",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "2.07"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 12",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.343",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "1.8",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-1.953",
  "ciUpperLimit": "5.469",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "1.83"
  }
  ]
  },
  {
  "type": "SECONDARY",
  "title": "Change From Baseline in Pustule Lesions at Weeks 2, 4, 8, and 12",
  "description": "Pustule - raised inflammatory lesions, \\<0.5 cm in diameter with visible purulent material",
  "populationDescription": "MITT population. Number of participants analyzed included participants with available data at specified visits.",
  "reportingStatus": "POSTED",
  "paramType": "LEAST_SQUARES_MEAN",
  "dispersionType": "Standard Error",
  "unitOfMeasure": "number of lesions",
  "timeFrame": "Baseline; Weeks 2, 4, 8, and 12",
  "groups": [
  {
  "id": "OG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks."
  },
  {
  "id": "OG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks."
  }
  ],
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "classes": [
  {
  "title": "Week 2",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-0.4",
  "spread": "0.43"
  },
  {
  "groupId": "OG001",
  "value": "-0.98",
  "spread": "0.62"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 4",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-1.2",
  "spread": "0.20"
  },
  {
  "groupId": "OG001",
  "value": "-1.63",
  "spread": "0.30"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 8",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-1.1",
  "spread": "0.25"
  },
  {
  "groupId": "OG001",
  "value": "-1.29",
  "spread": "0.38"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 12",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "26"
  },
  {
  "groupId": "OG001",
  "value": "11"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-1.0",
  "spread": "0.31"
  },
  {
  "groupId": "OG001",
  "value": "-1.04",
  "spread": "0.48"
  }
  ]
  }
  ]
  }
  ],
  "analyses": [
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 2",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.407",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "0.6",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-0.894",
  "ciUpperLimit": "2.155",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "0.75"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 4",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.291",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "0.4",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-0.342",
  "ciUpperLimit": "1.109",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "0.36"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 8",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.734",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "0.2",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-0.763",
  "ciUpperLimit": "1.073",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "0.45"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline in pustule lesions at Week 12",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.952",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "0.0",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-1.128",
  "ciUpperLimit": "1.197",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "0.57"
  }
  ]
  },
  {
  "type": "SECONDARY",
  "title": "Change From Baseline in Nodule Lesions at Weeks 2, 4, 8, and 12",
  "description": "Nodule - any circumscribed, inflammatory mass ≥0.5 cm in diameter",
  "populationDescription": "MITT population. Number of participants analyzed included participants with available data at specified visits.",
  "reportingStatus": "POSTED",
  "paramType": "LEAST_SQUARES_MEAN",
  "dispersionType": "Standard Error",
  "unitOfMeasure": "number of lesions",
  "timeFrame": "Baseline; Weeks 2, 4, 8, and 12",
  "groups": [
  {
  "id": "OG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks."
  },
  {
  "id": "OG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks."
  }
  ],
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "classes": [
  {
  "title": "Week 2",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "0.0",
  "spread": "0.04"
  },
  {
  "groupId": "OG001",
  "value": "0.02",
  "spread": "0.06"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 4",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "0.0",
  "spread": "0.04"
  },
  {
  "groupId": "OG001",
  "value": "-0.05",
  "spread": "0.06"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 8",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "0.0",
  "spread": "0.04"
  },
  {
  "groupId": "OG001",
  "value": "-0.05",
  "spread": "0.06"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 12",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "26"
  },
  {
  "groupId": "OG001",
  "value": "11"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "0.0",
  "spread": "0.04"
  },
  {
  "groupId": "OG001",
  "value": "0.04",
  "spread": "0.06"
  }
  ]
  }
  ]
  }
  ],
  "analyses": [
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 2",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.313",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "-0.1",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-0.215",
  "ciUpperLimit": "0.069",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "0.07"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 4",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.942",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "0.0",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-0.141",
  "ciUpperLimit": "0.152",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "0.07"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline in nodule lesions at Week 8",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.284",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "0.1",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-0.067",
  "ciUpperLimit": "0.226",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "0.07"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 12",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.542",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "0.0",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-0.198",
  "ciUpperLimit": "0.105",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "0.08"
  }
  ]
  },
  {
  "type": "SECONDARY",
  "title": "Change From Baseline in Papules + Pustules Lesions at Weeks 2, 4, 8, and 12",
  "description": "Papules + pustules lesions were the sum of counts of papule (raised inflammatory lesions, \\<0.5 cm in diameter with no visible purulent material) and pustule (raised inflammatory lesions, \\<0.5 cm in diameter with visible purulent material) lesions.",
  "populationDescription": "MITT population. Number of participants analyzed included participants with available data at specified visits.",
  "reportingStatus": "POSTED",
  "paramType": "LEAST_SQUARES_MEAN",
  "dispersionType": "Standard Error",
  "unitOfMeasure": "number of lesions",
  "timeFrame": "Baseline; Weeks 2, 4, 8, and 12",
  "groups": [
  {
  "id": "OG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks."
  },
  {
  "id": "OG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks."
  }
  ],
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "classes": [
  {
  "title": "Week 2",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-7.0",
  "spread": "1.16"
  },
  {
  "groupId": "OG001",
  "value": "-8.97",
  "spread": "1.67"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 4",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-10.9",
  "spread": "1.06"
  },
  {
  "groupId": "OG001",
  "value": "-9.90",
  "spread": "1.57"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 8",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-9.2",
  "spread": "1.19"
  },
  {
  "groupId": "OG001",
  "value": "-11.65",
  "spread": "1.75"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 12",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "26"
  },
  {
  "groupId": "OG001",
  "value": "11"
  }
  ]
  }
  ],
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "-10.2",
  "spread": "1.08"
  },
  {
  "groupId": "OG001",
  "value": "-12.03",
  "spread": "1.62"
  }
  ]
  }
  ]
  }
  ],
  "analyses": [
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 2",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.333",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "2.0",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-2.135",
  "ciUpperLimit": "6.139",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "2.04"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 4",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.591",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "-1.0",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-4.882",
  "ciUpperLimit": "2.822",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "1.90"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 8",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.254",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "2.5",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-1.840",
  "ciUpperLimit": "6.758",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "2.12"
  },
  {
  "groupIds": [
  "OG000",
  "OG001"
  ],
  "groupDescription": "Change from baseline at Week 12",
  "nonInferiorityType": "SUPERIORITY",
  "pValue": "0.356",
  "statisticalMethod": "t-test, 2 sided",
  "paramType": "Difference of LS Mean",
  "paramValue": "1.8",
  "ciPctValue": "95",
  "ciNumSides": "TWO_SIDED",
  "ciLowerLimit": "-2.131",
  "ciUpperLimit": "5.779",
  "dispersionType": "STANDARD_ERROR_OF_MEAN",
  "dispersionValue": "1.95"
  }
  ]
  },
  {
  "type": "SECONDARY",
  "title": "Number of Participants With Adverse Events",
  "description": "Number of participants reporting any adverse event including local tolerability of signs and symptoms of irritation, clinical laboratory safety tests, and vital signs.",
  "populationDescription": "Safety population included all randomized participants who received at least 1 dose of study medication.",
  "reportingStatus": "POSTED",
  "paramType": "COUNT_OF_PARTICIPANTS",
  "unitOfMeasure": "Participants",
  "timeFrame": "Baseline to Week 14",
  "groups": [
  {
  "id": "OG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks."
  },
  {
  "id": "OG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks."
  }
  ],
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "classes": [
  {
  "categories": [
  {
  "measurements": [
  {
  "groupId": "OG000",
  "value": "11"
  },
  {
  "groupId": "OG001",
  "value": "4"
  }
  ]
  }
  ]
  }
  ]
  },
  {
  "type": "OTHER_PRE_SPECIFIED",
  "title": "Number of Participants With Erythema Score Based on Local Tolerability as Assessed by the Investigator at Week 12",
  "description": "Erythema score was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.\n\nScore 0 (clear): no erythema present\n\nScore 1 (mild): slight erythema\n\nScore 2 (moderate): definite erythema\n\nScore 3 (severe): marked, fiery erythema",
  "populationDescription": "Safety population included all randomized participants who received at least 1 dose of study medication. Number of participants analyzed included participants with available data at specified timepoints.",
  "reportingStatus": "POSTED",
  "paramType": "COUNT_OF_PARTICIPANTS",
  "unitOfMeasure": "Participants",
  "timeFrame": "Week 12",
  "groups": [
  {
  "id": "OG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks."
  },
  {
  "id": "OG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks."
  }
  ],
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "26"
  },
  {
  "groupId": "OG001",
  "value": "11"
  }
  ]
  }
  ],
  "classes": [
  {
  "categories": [
  {
  "title": "Score 0 (clear)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "1"
  },
  {
  "groupId": "OG001",
  "value": "1"
  }
  ]
  },
  {
  "title": "Score 1 (mild)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "14"
  },
  {
  "groupId": "OG001",
  "value": "3"
  }
  ]
  },
  {
  "title": "Score 2 (moderate)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "9"
  },
  {
  "groupId": "OG001",
  "value": "6"
  }
  ]
  },
  {
  "title": "Score 3 (severe)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "2"
  },
  {
  "groupId": "OG001",
  "value": "1"
  }
  ]
  }
  ]
  }
  ]
  },
  {
  "type": "OTHER_PRE_SPECIFIED",
  "title": "Number of Participants With Erythema Score Based on Local Tolerability as Assessed by the Investigator at Day 1 (Post-application) and Weeks 2, 4, 8, and 14",
  "description": "Erythema score was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.\n\nScore 0 (clear): no erythema present\n\nScore 1 (mild): slight erythema\n\nScore 2 (moderate): definite erythema\n\nScore 3 (severe): marked, fiery erythema",
  "populationDescription": "Safety population. Number of participants analyzed included participants with available data at specified timepoints.",
  "reportingStatus": "POSTED",
  "paramType": "COUNT_OF_PARTICIPANTS",
  "unitOfMeasure": "Participants",
  "timeFrame": "Day 1 (Post-application) and Weeks 2, 4, 8, and 14",
  "groups": [
  {
  "id": "OG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks."
  },
  {
  "id": "OG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks."
  }
  ],
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "classes": [
  {
  "title": "Day 1 (Post-application)",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "categories": [
  {
  "title": "Score 0 (clear)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "1"
  },
  {
  "groupId": "OG001",
  "value": "1"
  }
  ]
  },
  {
  "title": "Score 1 (mild)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "9"
  },
  {
  "groupId": "OG001",
  "value": "4"
  }
  ]
  },
  {
  "title": "Score 2 (moderate)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "12"
  },
  {
  "groupId": "OG001",
  "value": "4"
  }
  ]
  },
  {
  "title": "Score 3 (severe)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "5"
  },
  {
  "groupId": "OG001",
  "value": "4"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 2",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "13"
  }
  ]
  }
  ],
  "categories": [
  {
  "title": "Score 0 (clear)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "0"
  },
  {
  "groupId": "OG001",
  "value": "0"
  }
  ]
  },
  {
  "title": "Score 1 (mild)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "12"
  },
  {
  "groupId": "OG001",
  "value": "7"
  }
  ]
  },
  {
  "title": "Score 2 (moderate)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "12"
  },
  {
  "groupId": "OG001",
  "value": "4"
  }
  ]
  },
  {
  "title": "Score 3 (severe)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "3"
  },
  {
  "groupId": "OG001",
  "value": "2"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 4",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "title": "Score 0 (clear)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "0"
  },
  {
  "groupId": "OG001",
  "value": "0"
  }
  ]
  },
  {
  "title": "Score 1 (mild)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "13"
  },
  {
  "groupId": "OG001",
  "value": "4"
  }
  ]
  },
  {
  "title": "Score 2 (moderate)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "12"
  },
  {
  "groupId": "OG001",
  "value": "7"
  }
  ]
  },
  {
  "title": "Score 3 (severe)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "2"
  },
  {
  "groupId": "OG001",
  "value": "1"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 8",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "27"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "title": "Score 0 (clear)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "1"
  },
  {
  "groupId": "OG001",
  "value": "1"
  }
  ]
  },
  {
  "title": "Score 1 (mild)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "11"
  },
  {
  "groupId": "OG001",
  "value": "5"
  }
  ]
  },
  {
  "title": "Score 2 (moderate)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "13"
  },
  {
  "groupId": "OG001",
  "value": "6"
  }
  ]
  },
  {
  "title": "Score 3 (severe)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "2"
  },
  {
  "groupId": "OG001",
  "value": "0"
  }
  ]
  }
  ]
  },
  {
  "title": "Week 14",
  "denoms": [
  {
  "units": "Participants",
  "counts": [
  {
  "groupId": "OG000",
  "value": "26"
  },
  {
  "groupId": "OG001",
  "value": "12"
  }
  ]
  }
  ],
  "categories": [
  {
  "title": "Score 0 (clear)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "2"
  },
  {
  "groupId": "OG001",
  "value": "1"
  }
  ]
  },
  {
  "title": "Score 1 (mild)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "8"
  },
  {
  "groupId": "OG001",
  "value": "3"
  }
  ]
  },
  {
  "title": "Score 2 (moderate)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "13"
  },
  {
  "groupId": "OG001",
  "value": "5"
  }
  ]
  },
  {
  "title": "Score 3 (severe)",
  "measurements": [
  {
  "groupId": "OG000",
  "value": "3"
  },
  {
  "groupId": "OG001",
  "value": "3"
  }
  ]
  }
  ]
  }
  ]
  }
  ]
  },
  "adverseEventsModule": {
  "frequencyThreshold": "0",
  "timeFrame": "Baseline up to Week 14",
  "description": "Safety population",
  "eventGroups": [
  {
  "id": "EG000",
  "title": "ACU-D1 Ointment",
  "description": "Twice-daily application of ACU-D1 ointment to the face for 12 weeks.",
  "deathsNumAffected": 0,
  "deathsNumAtRisk": 27,
  "seriousNumAffected": 0,
  "seriousNumAtRisk": 27,
  "otherNumAffected": 11,
  "otherNumAtRisk": 27
  },
  {
  "id": "EG001",
  "title": "ACU-D1 Ointment Vehicle",
  "description": "Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.",
  "deathsNumAffected": 0,
  "deathsNumAtRisk": 13,
  "seriousNumAffected": 0,
  "seriousNumAtRisk": 13,
  "otherNumAffected": 4,
  "otherNumAtRisk": 13
  }
  ],
  "otherEvents": [
  {
  "term": "Vomiting",
  "organSystem": "Gastrointestinal disorders",
  "sourceVocabulary": "MedDRA (21.0)",
  "assessmentType": "SYSTEMATIC_ASSESSMENT",
  "stats": [
  {
  "groupId": "EG000",
  "numAffected": 1,
  "numAtRisk": 27
  },
  {
  "groupId": "EG001",
  "numAffected": 0,
  "numAtRisk": 13
  }
  ]
  },
  {
  "term": "Administration site dryness",
  "organSystem": "General disorders",
  "sourceVocabulary": "MedDRA (21.0)",
  "assessmentType": "SYSTEMATIC_ASSESSMENT",
  "stats": [
  {
  "groupId": "EG000",
  "numAffected": 1,
  "numAtRisk": 27
  },
  {
  "groupId": "EG001",
  "numAffected": 1,
  "numAtRisk": 13
  }
  ]
  },
  {
  "term": "Administration site warmth",
  "organSystem": "General disorders",
  "sourceVocabulary": "MedDRA (21.0)",
  "assessmentType": "SYSTEMATIC_ASSESSMENT",
  "stats": [
  {
  "groupId": "EG000",
  "numAffected": 1,
  "numAtRisk": 27
  },
  {
  "groupId": "EG001",
  "numAffected": 0,
  "numAtRisk": 13
  }
  ]
  },
  {
  "term": "Application site perspiration",
  "organSystem": "General disorders",
  "sourceVocabulary": "MedDRA (21.0)",
  "assessmentType": "SYSTEMATIC_ASSESSMENT",
  "stats": [
  {
  "groupId": "EG000",
  "numAffected": 1,
  "numAtRisk": 27
  },
  {
  "groupId": "EG001",
  "numAffected": 0,
  "numAtRisk": 13
  }
  ]
  },
  {
  "term": "Ear infection",
  "organSystem": "Infections and infestations",
  "sourceVocabulary": "MedDRA (21.0)",
  "assessmentType": "SYSTEMATIC_ASSESSMENT",
  "stats": [
  {
  "groupId": "EG000",
  "numAffected": 1,
  "numAtRisk": 27
  },
  {
  "groupId": "EG001",
  "numAffected": 0,
  "numAtRisk": 13
  }
  ]
  },
  {
  "term": "Nasopharyngitis",
  "organSystem": "Infections and infestations",
  "sourceVocabulary": "MedDRA (21.0)",
  "assessmentType": "SYSTEMATIC_ASSESSMENT",
  "stats": [
  {
  "groupId": "EG000",
  "numAffected": 2,
  "numAtRisk": 27
  },
  {
  "groupId": "EG001",
  "numAffected": 2,
  "numAtRisk": 13
  }
  ]
  },
  {
  "term": "Respiratory tract infection",
  "organSystem": "Infections and infestations",
  "sourceVocabulary": "MedDRA (21.0)",
  "assessmentType": "SYSTEMATIC_ASSESSMENT",
  "stats": [
  {
  "groupId": "EG000",
  "numAffected": 1,
  "numAtRisk": 27
  },
  {
  "groupId": "EG001",
  "numAffected": 0,
  "numAtRisk": 13
  }
  ]
  },
  {
  "term": "Sinusitis",
  "organSystem": "Infections and infestations",
  "sourceVocabulary": "MedDRA (21.0)",
  "assessmentType": "SYSTEMATIC_ASSESSMENT",
  "stats": [
  {
  "groupId": "EG000",
  "numAffected": 1,
  "numAtRisk": 27
  },
  {
  "groupId": "EG001",
  "numAffected": 0,
  "numAtRisk": 13
  }
  ]
  },
  {
  "term": "Tibia fracture",
  "organSystem": "Injury, poisoning and procedural complications",
  "sourceVocabulary": "MedDRA (21.0)",
  "assessmentType": "SYSTEMATIC_ASSESSMENT",
  "stats": [
  {
  "groupId": "EG000",
  "numAffected": 1,
  "numAtRisk": 27
  },
  {
  "groupId": "EG001",
  "numAffected": 0,
  "numAtRisk": 13
  }
  ]
  },
  {
  "term": "White blood cell count decreased",
  "organSystem": "Investigations",
  "sourceVocabulary": "MedDRA (21.0)",
  "assessmentType": "SYSTEMATIC_ASSESSMENT",
  "stats": [
  {
  "groupId": "EG000",
  "numAffected": 0,
  "numAtRisk": 27
  },
  {
  "groupId": "EG001",
  "numAffected": 1,
  "numAtRisk": 13
  }
  ]
  },
  {
  "term": "Vitamin D deficiency",
  "organSystem": "Metabolism and nutrition disorders",
  "sourceVocabulary": "MedDRA (21.0)",
  "assessmentType": "SYSTEMATIC_ASSESSMENT",
  "stats": [
  {
  "groupId": "EG000",
  "numAffected": 1,
  "numAtRisk": 27
  },
  {
  "groupId": "EG001",
  "numAffected": 0,
  "numAtRisk": 13
  }
  ]
  },
  {
  "term": "Cough",
  "organSystem": "Respiratory, thoracic and mediastinal disorders",
  "sourceVocabulary": "MedDRA (21.0)",
  "assessmentType": "SYSTEMATIC_ASSESSMENT",
  "stats": [
  {
  "groupId": "EG000",
  "numAffected": 0,
  "numAtRisk": 27
  },
  {
  "groupId": "EG001",
  "numAffected": 1,
  "numAtRisk": 13
  }
  ]
  }
  ]
  },
  "moreInfoModule": {
  "certainAgreement": {
  "piSponsorEmployee": false,
  "restrictiveAgreement": false
  },
  "pointOfContact": {
  "title": "Chief Science Officer",
  "organization": "Accuitis, Inc.",
  "email": "info@accuitis.com",
  "phone": "678-812-1492"
  }
  }
  },
  "documentSection": {
  "largeDocumentModule": {
  "largeDocs": [
  {
  "typeAbbrev": "Prot",
  "hasProtocol": true,
  "hasSap": false,
  "hasIcf": false,
  "label": "Study Protocol",
  "date": "2017-08-05",
  "uploadDate": "2021-08-13T11:54",
  "filename": "Prot_000.pdf",
  "size": 642802
  },
  {
  "typeAbbrev": "SAP",
  "hasProtocol": false,
  "hasSap": true,
  "hasIcf": false,
  "label": "Statistical Analysis Plan",
  "date": "2018-05-11",
  "uploadDate": "2021-08-13T11:56",
  "filename": "SAP_001.pdf",
  "size": 7296067
  }
  ]
  }
  },
  "annotationSection": {
  "annotationModule": {
  "violationAnnotation": {
  "violationEvents": [
  {
  "type": "CORRECTION_CONFIRMED",
  "description": "The responsible party has corrected the violation.",
  "creationDate": "2022-06-06",
  "issuedDate": "2022-05-26",
  "releaseDate": "2021-08-17",
  "postedDate": "2022-06-07"
  },
  {
  "type": "VIOLATION_IDENTIFIED",
  "description": "Failure to Submit. The entry for this clinical trial was not complete at the time of submission, as required by law. This may or may not have any bearing on the accuracy of the information in the entry.",
  "creationDate": "2021-07-28",
  "issuedDate": "2021-07-26",
  "releaseDate": "2018-04-12",
  "postedDate": "2021-07-29"
  }
  ]
  }
  }
  },
  "derivedSection": {
  "miscInfoModule": {
  "versionHolder": "2024-01-03",
  "modelPredictions": {
  "bmiLimits": {
  "minBmi": 0,
  "maxBmi": 101
  }
  }
  },
  "conditionBrowseModule": {
  "meshes": [
  {
  "id": "D000012393",
  "term": "Rosacea"
  }
  ],
  "ancestors": [
  {
  "id": "D000012871",
  "term": "Skin Diseases"
  }
  ],
  "browseLeaves": [
  {
  "id": "M3202",
  "name": "Acne Vulgaris",
  "relevance": "LOW"
  },
  {
  "id": "M14904",
  "name": "Rosacea",
  "asFound": "Rosacea",
  "relevance": "HIGH"
  },
  {
  "id": "M15364",
  "name": "Skin Diseases",
  "relevance": "LOW"
  }
  ],
  "browseBranches": [
  {
  "abbrev": "BC17",
  "name": "Skin and Connective Tissue Diseases"
  },
  {
  "abbrev": "All",
  "name": "All Conditions"
  }
  ]
  }
  },
  "hasResults": true
  }